Para-Methoxymethamphetamine (PMMA) in tablets sold as ecstasy: Why this matters across our workforce
A recent UNODC alert highlights increasing detections of para-methoxymethamphetamine (PMMA) in tablets sold as ecstasy across several European countries. Its slower onset can lead people to take more before the full effects develop, increasing the risk of serious toxicity. Tablet colour, shape or logo cannot reliably tell us what is inside.
For the ISSUP community, this is a useful reminder that changing drug markets matter across our work. Prevention practitioners can use alerts to support credible, non-judgemental conversations about uncertain drug contents, while treatment teams can keep clinical awareness current and strengthen links with toxicology and early warning services. Recovery practitioners and peer networks can help information reach communities, create space for questions and encourage timely help-seeking. Law enforcement and others working in drug supply reduction also have an important contribution to make by connecting seizure intelligence and forensic findings with public health responses. Sharing information across these sectors helps turn emerging signals into coordinated action.
While these recent reports come from Europe, PMMA has been detected across all continents in the past. This does not confirm its presence locally, but it gives us a good reason to check how emerging drug alerts are shared and acted on in our own settings.
